Testing if a blood test can guide treatment after surgery for early lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is looking at whether using a sensitive blood test to find tiny bits of cancer left after surgery can help guide whether extra treatment is needed. The goal is to see if this approach is better than standard care for early-stage lung cancer patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (the most common type) confirmed by a biopsy.
- You had surgery to completely remove the cancer, and it was Stage IA or IB (early stage).
- You are fully recovered from surgery with no signs of cancer left.
- You are between 18 and 75 years old and are in fairly good health (able to do light activity).
- You have not had any prior cancer treatments like chemotherapy, radiation, or targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.